Press Releases
Lung Cancer
-
Jennerex Publishes Data on JX-594 Cancer Targeting Mechanisms
Jennerex Publishes Data on JX-594 Cancer Targeting Mechanisms -- JX-594 Selectivity is Multi-Mechanistic, Driven by Genetic Traits Common in Solid Tumors -- PR Newswire SAN FRANCISCO , Feb. 7, 2012 /PRNewswire/...
-
Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others
Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others PR Newswire NEW YORK , Feb. 6, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market...
-
The Importance of Applying for SSDI Benefits After a Serious Diagnosis
It can take several months before SSDI benefits are approved. Because SSDI benefits provide crucial support, it is important to file for them as soon as possible. February 04, 2012 /24-7PressRelease/ -- The Importance of Applying for SSDI...
-
Team Led By Scripps Research Scientists Demonstrates Effective New 'Biopsy in a Blood Test' to Detect Cancer
Team Led By Scripps Research Scientists Demonstrates Effective New 'Biopsy in a Blood Test' to Detect Cancer PR Newswire Series of Five Studies Highlights Potential of Technology to Boost Patient Care, Research LA...
-
Critical Outcome Technologies Inc. Identifies Phase 1 Oral Formulation Candidates for COTI-2
Critical Outcome Technologies Inc. (COTI) (TSX VENTURE:COT) announced today that it has developed Phase 1 oral formulation candidates for COTI-2, a potentially first-in-class and best-in-class non-ATP competitive modulator/inhibitor of AKT/AKT2...
-
High Triglyceride Levels Found to Predict Stroke in Older Women
High Triglyceride Levels Found to Predict Stroke in Older Women PR Newswire A Stronger Link than Cholesterol Levels to Ischemic Stroke BRONX, N.Y. , Feb. 2, 2012 /PRNewswire-USNewswire/ -- In a surprising finding...
-
Phase 1 Study of OGX-427 Presented at the ASCO 2012 Genitourinary Cancers Symposium Shows Early Evidence of Activity in Bladder Cancer
Phase 1 Study of OGX-427 Presented at the ASCO 2012 Genitourinary Cancers Symposium Shows Early Evidence of Activity in Bladder Cancer Data Support Ongoing Phase 2 Study in Metastatic Bladder Cancer PR Newswire BOTHELL, Wash. and...
-
Clinical Data on OGX-427 Presented at the ASCO 2012 Genitourinary Cancers Symposium Provide Ongoing Evidence of Hsp27 as a Potential Therapeutic Target in Advanced Prostate Cancer
Clinical Data on OGX-427 Presented at the ASCO 2012 Genitourinary Cancers Symposium Provide Ongoing Evidence of Hsp27 as a Potential Therapeutic Target in Advanced Prostate Cancer OncoGenex Announces Plans to Initiate a Phase 2 Study of OGX-427...
-
YouTube Interview Now Available for Kedem Pharmaceuticals CEO Dr. Hassan Salari Updating Company Progress on Sublingual Drug Delivery System
Kedem Pharmaceuticals Inc. (OTCBB: KDMP), a specialty pharmaceutical company with focus on sublingual drug delivery, is pleased to announce the company CEO Dr. Hassan Salari providing an update on the company's progress on YouTube for the Company's...
-
Nitric Oxide - Therapeutics, Markets and Companies
Nitric Oxide - Therapeutics, Markets and Companies PR Newswire NEW YORK , Feb. 2, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Nitric Oxide - Therapeutics, Markets...
-
Agennix AG Halts Phase II/III OASIS Trial in Severe Sepsis
Agennix AG (FRANKFURT: AGX) (XETRA: AGX) (ISIN DE000A1A6XX4) announced that, upon the recommendation of the study Data Safety Monitoring Board (DSMB), the Company has stopped further enrollment and treatment in the Phase II/III OASIS trial with...
-
The RARE List™ - You Must See it to Believe it!
The RARE List™ - You Must See it to Believe it! PR Newswire 7,000 Different Rare Diseases and Disorders Comprise 65 Page RARE List™, 95% of the Medical Conditions Included on RARE List™ Have No FDA Approved Treatments DANA...
-
Personalized Medicine - Scientific & Commercial Aspects
Personalized Medicine - Scientific & Commercial Aspects PR Newswire NEW YORK , Feb. 1, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Personalized...
-
Proteomics - Technologies, Markets and Companies
Proteomics - Technologies, Markets and Companies PR Newswire NEW YORK , Feb. 1, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Proteomics - Technologies, Markets...
-
Biochips and Microarrays - Technologies, Markets and Companies
Biochips and Microarrays - Technologies, Markets and Companies PR Newswire NEW YORK , Feb. 1, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Biochips...
Follow us
What people say
Our Partners
© 2005-2012